AL (AL) 24-hour amplitude reaches 314.2%: Price surges to $0.012 before quick pullback
Bitget Pulse2026/05/10 10:55Volatility Overview
In the past 24 hours, AL price experienced significant volatility: dropping to a low of $0.002897 and surging to a high of $0.012. The current quote is $0.00333, with a price swing as high as 314.2%. Public market data shows no significant spike in trading volume, net capital inflows/outflows, or other key indicators (no high-volume data on CoinGecko, CoinMarketCap, or DEXScreener).
Brief Analysis of Abnormal Movements
- In the past 24 hours, there were no major news releases, official announcements, on-chain monitoring (such as Dune, Nansen), or large whale transactions directly driving the movement.
- No corresponding price pumps were found via DEXScreener and X platform search. This may be a typical short-term speculative fluctuation of a low-liquidity token, with no verifiable primary cause.
Market Views and Outlook
There has been limited discussion from the market and communities regarding this volatility, with no mainstream sentiment or analyst predictions (X search only had sporadic mentions of similar tickers like ALGO/ALCH, but prices did not match). Going forward, it is important to be cautious of high volatility risks and to pay attention to liquidity and potential rug-pull warnings.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
